Brockert v. WYETH PHARMACEUTICALS, INC.

OPINION

JEFFREY V. BROWN, Justice.

In this case, appellant Susan Brockert raises two issues: (1) whether federal law preempts her failure-to-warn claims arising from her use of a prescription drug containing estrogen combined with proges-tin in hormone-replacement therapy; and (2) whether her design-defect claim that estrogen alone is a superior form of hormone-replacement therapy compared to estrogen with progestin is viable under Texas strict-liability and negligence law. For the reasons explained below, we hold that federal law does not preempt Broc-kert’s failure-to-warn claims, but her…